Piro Lito

Biochemistry, Genetics and Molecular BiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 20 papers. Top paper: “Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy”.

Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy

Nature(2024)10.1038/s41586-024-07205-6

N/A

4.2DataRank · unranked

326 citations

Bianca J. Lee, Jingjing Jiang, Aidan C.A. Tomlinson, Kyle J. Seamon, Alessia Mira +48 more

Chemical remodeling of a cellular chaperone to target the active state of mutant KRAS

Science(2023)10.1126/science.adg9652

N/A

4.2DataRank · unranked

237 citations

Kyle J. Seamon, Yulei Zhao, Yu Chi Yang, Jim Cregg, Dong-Sung Kim +31 more

RAS-mutant leukaemia stem cells drive clinical resistance to venetoclax

Nature(2024)10.1038/s41586-024-08137-x

N/A

1.7DataRank · unranked

86 citations

Saul Carcamo, Maria Sirenko, Abhishek Maiti, Hager Mansour, Gulay Ulukaya +23 more

Pharmacological restoration of GTP hydrolysis by mutant RAS

Nature(2024)10.1038/s41586-024-08283-2

N/A

1.2DataRank · unranked

44 citations

Yasin Pourfarjam, Feng Hu, Diego J. Rodriguez, Alberto Vides, Ben Sang +5 more

Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition

Nature(2020)10.1038/s41586-019-1884-x

N/A

0.947DataRank · unranked

552 citations

Yulei Zhao, Jordan Aronowitz, Trang T. Mai, Alberto Vides, Besnik Qeriqi +7 more

Diverse alterations associated with resistance to KRAS(G12C) inhibition

Nature(2021)10.1038/s41586-021-04065-2

N/A

0.919DataRank · unranked

458 citations

Yonina R. Murciano‐Goroff, Jenny Y. Xue, Agnes Ang, Jessica Lucas, Trang T. Mai +23 more

COVID-19 in patients with lung cancer

Annals of Oncology(2020)10.1016/j.annonc.2020.06.007

N/A

0.840DataRank · unranked

270 citations

Hira Rizvi, Isabel R. Preeshagul, Jacklynn V. Egger, David Hoyos, Chai Bandlamudi +26 more

Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer

Nature Medicine(2022)10.1038/s41591-022-02047-z

N/A

0.792DataRank · unranked

195 citations

Emily S. Lebow, Randy Yeh, Jeeban Paul Das, Azadeh Namakydoust, Paul K. Paik +67 more

Treatment Outcomes and Clinical Characteristics of Patients with KRAS-G12C–Mutant Non–Small Cell Lung Cancer

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-20-4023

N/A

0.725DataRank · unranked

125 citations

Hira Rizvi, Andrew J. Plodkowski, Matthew D. Hellmann, Andrea Knežević, Glenn Heller +8 more

Modeling lung adenocarcinoma metastases using patient-derived organoids

Cell Reports Medicine(2024)10.1016/j.xcrm.2024.101777

N/A

0.470DataRank · unranked

22 citations

Manendra B. Lankadasari, Joel Rosiene, Kofi E. Johnson, Juan Zhou, Samhita Bapat +23 more

Phase 1 Clinical Trial of Trametinib and Ponatinib in Patients With NSCLC Harboring KRAS Mutations

JTO Clinical and Research Reports(2021)10.1016/j.jtocrr.2021.100256

N/A

0.396DataRank · unranked

13 citations

Eusebio Manchado, Matthew J. Bott, Linda S. Ahn, Yosef Y. Tobi, Andy Ai Ni +14 more

Outcomes of Combination Platinum-Doublet Chemotherapy and Anti-PD(L)-1 Blockade in KRASG12C-Mutant Non-Small Cell Lung Cancer

The Oncologist(2023)10.1093/oncolo/oyad197

N/A

0.385DataRank · unranked

12 citations

Biagio Ricciuti, Joao V. Alessi, Teng Fei, Hannah L. Kalvin, Jacklynn V. Egger +16 more

Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy

10.21203/rs.3.rs-3122478/v1

N/A

0.292DataRank · unranked

6 citations

Matthew Holderfield, Bianca Lee, Jingjing Jiang, Aidan Tomlinson, Kyle Seamon +44 more

Data from Adaptive Resistance to Dual BRAF/MEK Inhibition in BRAF-Driven Tumors through Autocrine FGFR Pathway Activation

(2023)10.1158/1078-0432.c.6527784.v1

N/A

0DataRank · unranked

0 citations

Jenny Y. Xue, Dennie T. Frederick, Yi Cao, Eva Lin, Catherine Wilson +8 more

Clinicopathologic characterization of ERK2 E322K mutation in solid tumors: Implications for treatment and drug development.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.3135

N/A

0DataRank · unranked

0 citations

Yonina R. Murciano‐Goroff, Justin Jee, Maria E. Arcila, Darren J. Buonocore, Jianjiong Gao +15 more

Pan-KRAS inhibitor disables oncogenic signalling and tumour growth

Nature(2023)10.1038/s41586-023-06123-3

N/A

0DataRank · unranked

506 citations

Lorenz Herdeis, Dorothea Rudolph, Yulei Zhao, Jark Böttcher, Alberto Vides +19 more

Suppressing Nucleotide Exchange to Inhibit KRAS-Mutant Tumors

Cancer Discovery(2021)10.1158/2159-8290.cd-20-1331

N/A

0DataRank · unranked

20 citations

Jenny Y. Xue, Piro Lito, Yulei Zhao

Targeting KRAS(G12C): From Inhibitory Mechanism to Modulation of Antitumor Effects in Patients

Cell(2020)10.1016/j.cell.2020.09.044

N/A

0DataRank · unranked

249 citations

Jenny Y. Xue, Piro Lito, Dong-Sung Kim

Insights into how adeno-squamous transition drives KRAS inhibitor resistance

Cancer Cell(2024)10.1016/j.ccell.2024.02.014

N/A

0DataRank · unranked

9 citations

Piro Lito, Feng Hu

Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy

UNC Libraries(2024)10.17615/1fr6-tv06

N/A

0DataRank · unranked

0 citations

Nicole Nasholm, Chiara Ambrogio, Anthony N. Milin, Yang Liu, Elsa Quintana +48 more